地塞米松与泼尼松对COVID-19患者阿哌沙班和利伐沙班暴露影响的PBPK建模研究
本研究采用生理药代动力学(PBPK)建模,在COVID-19患者群体中优化地塞米松(DEX)的诱导效应参数,模拟DEX对阿哌沙班(APX)和利伐沙班(RVX)药代动力学的影响。结果显示,在最坏情景下且DEX 6 mg口服10天时,APX和RVX的AUC降低20%,支持低血栓栓塞风险的COVID-19患者联用APX/RVX与DEX;等效剂量泼尼松(PRED)因诱导效应较弱或可替代DEX。
要点
- DEX 6 mg口服10天最坏情景下,APX和RVX的AUC降低20%。
- 低血栓栓塞风险COVID-19患者可联用APX/RVX与DEX。
- 等效剂量PRED对APX/RVX诱导效应较弱,或可替代DEX。
核心结论
- PBPK模拟显示DEX 6 mg口服10天最坏情景下APX和RVX的AUC降低20%,支持低血栓栓塞风险COVID-19患者联用。
- 等效剂量PRED因对APX和RVX诱导效应较弱,可能作为DEX的替代选择。
研究设计与样本
- 采用生理药代动力学(PBPK)建模,在COVID-19患者群体中优化DEX的诱导效应参数。
- 利用有限已有研究验证DEX对两种CYP3A4底物的诱导效应。
主要发现
- COVID-19患者中观察到的DEX血浆浓度显著高于健康志愿者。
- PBPK模拟显示最坏情景下且DEX 6 mg口服10天时,APX和RVX的AUC降低20%。
关键数值与推荐
- DEX给药方案为6 mg口服10天。
- APX和RVX的AUC降低20%对应最坏情景。
临床怎么用
- 低血栓栓塞风险的COVID-19患者可使用APX和RVX与DEX联用。
- 等效剂量PRED可考虑作为DEX的替代,因其对APX和RVX诱导效应较弱。
局限性
- 需进一步研究验证这些发现并探索以PRED替代DEX的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dexamethasone (DEX) is currently the treatment of choice for patients with oxygen-dependent COVID-19. It has been observed, primarily in vitro, that dexamethasone induces the expression of CYP3A and the ABCB1 gene, which encodes P-glycoprotein (P-gp). This has raised concerns about potential interactions between DEX and substrates of CYP3A and P-gp, such as direct oral anticoagulants (DOAC). Currently, there is limited robust evidence to support a clinically significant interaction between DEX and DOAC. Using physiologically based pharmacokinetic modeling (PBPK), we investigated the impact of DEX administered in the context of SARS-CoV-2 infection on the pharmacokinetics of apixaban (APX) and rivaroxaban (RVX). After validating the induction effect of the DEX compound on two CYP3A4 substrates using the limited available studies, we optimized the compound in a COVID-19 patient population, where significantly higher DEX plasma concentrations were observed compared to healthy volunteers. Our PBPK-based PK simulations showed a 20% decrease in the AUC of APX and RVX in a worst-case scenario and when DEX was administered at 6 mg PO for 10 days. This finding confirms the limited clinical data currently available and supports the use of APX and RVX with DEX in COVID-19 patients at low-risk for thrombo-embolism. In addition, our results suggest that prednisone (PRED), when used at an equipotent dose, could serve as a viable alternative to DEX, given its less pronounced induction effect on APX and RVX. Further research is needed to validate these findings and to explore the clinical implications of using PRED in place of DEX in such scenarios.
引用
- Terrier J, Abouir K, Gaspar F, et al. The Impact of Dexamethasone and Prednisone on Apixaban and Rivaroxaban Exposure in COVID-19 Patients: A Physiologically Based Pharmacokinetic Modeling Study. Clin Pharmacol Ther. 2024. PMID: 39535447. doi:10.1002/cpt.3491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。